Assessment of Abuse Potential of Rapastinel in Humans
Status:
Completed
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate
the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR
antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational
polydrug users.